Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000755 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 10
- Study locations
NCT00000755: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000755 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 168 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000755, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 10
- Study locations
Study Summary
To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
Conditions Studied
Interventions
- DRUG Zidovudine
- BIOLOGICAL rgp120/HIV-1MN
Study Locations (10)
Massachusetts
- Massachusetts General Hospital ACTG CRS - Boston
- Bmc Actg Crs - Boston
- Beth Israel Deaconess - East Campus A0102 CRS - Boston
- Beth Israel Deaconess Med. Ctr., ACTG CRS - Boston
California
- UCLA CARE Center CRS - Los Angeles
- Stanford CRS - Palo Alto
- Ucsf Aids Crs - San Francisco
Colorado
- University of Colorado Hospital CRS - Aurora
New York
- NY Univ. HIV/AIDS CRS - New York
Washington
- University of Washington AIDS CRS - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Est. Completion | 1993-03 |
| Phase | Phase 1 |
What the finished NCT00000755 record still lists
NCT00000755 is an interventional study that assigns participants to a tested intervention. The registered 168 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (62% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Zidovudine is the first listed.
NCT00000755 lists 10 locations in 5 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT00000755 about?
NCT00000755 is a clinical study titled "A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3". To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immun...
What is the current status of trial NCT00000755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 168 participants. Estimated completion is 1993-03.
What conditions does trial NCT00000755 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00000755?
The interventions under investigation include: Zidovudine (DRUG), rgp120/HIV-1MN (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000755?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000755 being conducted?
This trial has 10 study locations across California, Colorado, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000755's enrollment target sits among peer trials
168 196th of 542 higher than 344 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
- NCT03536897 · 168 participants
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
- NCT04078230 · 168 participants · NA
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- NCT04159168 · 168 participants · NA
Facial Affect Sensitivity Training for Young Children With Callous-unemotional Traits